ClinicalTrials.gg
CompletedNCT00966940Updated Jun 20, 2012Results posted

Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

A Phase 4 interventional study of Travoprost 0.004% ophthalmic solution (TRAVATAN) and Tafluprost 0.0015% ophthalmic solution in Glaucoma, sponsored by Alcon Research. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2012-06-20.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.

Enrollment
28th of 39
51 · median 89
Started
2009
the only one that year
Phase 4
25 of 42
none open now
Registered
25th of 42
by date
Lead sponsor
27 of 42
Alcon Research

Among the 42 studies testing travoprost in Glaucoma, this one is the 28th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2009, is one of 25 in phase 4, and was the 25th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 155 Glaucoma studies recruiting now, 113 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing travoprost in Glaucoma as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • Glaucoma
  • IOP
  • Travoprost
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An EC-reviewed and approved (for use in this study) form must be read, signed, and dated by the participating patient as well as signed and dated by the individual (Principal Investigator or other site personnel) obtaining the informed consent, before conducting the Screening Visit and prior to initiation of study procedures.
  • Patients must be at least 21 years of age.
  • Must be able to follow instructions and be willing and able to attend required study visits.
  • Must have a clinical diagnosis of ocular hypertension or primary open-angle glaucoma in at least one eye (qualifying eye).
  • Currently treated patients, in the investigator's judgment, should require a change in treatment for reasons of improved efficacy, tolerability or compliance.
  • Must have IOP considered to be safe, in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the trial.
  • Must have an intraocular pressure of > 21 mm Hg in at least one eye at 08:00 and > 19 mm Hg in the same eye at 16:00, and \< 35 mm Hg in both eyes at all diurnal time points at Visit 2.
  • Must have best corrected visual acuity of 6/60 (20/200 Snellen) or better in each eye.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Presence of other primary or secondary glaucomas not listed in inclusion criterion.
  • Presence of extreme narrow angle with complete or partial closure in either eye, as measured by gonioscopy (occludable angles treated with a patent iridectomy are acceptable).
  • Any abnormality preventing reliable applanation tonometry in qualifying eye(s).
  • Any opacity or patient uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber of either eye.
  • Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye. Blepharitis or non- conjunctival injection is allowed.
  • Intraocular conventional surgery or laser surgery in qualifying eye(s) less than three months prior to Visit 1.
  • Risk of visual field or visual acuity worsening as a consequence of participation in the trial, in the investigator's best judgment.
  • Progressive retinal or optic nerve disease from any cause apart from glaucoma.
  • Women of not using reliable means of , or pregnant or lactating females.
  • Any clinically significant, serious, or severe medical or psychiatric condition.
  • A condition, which in the opinion of the investigator, would interfere with optimal participation in the study, or which would present a special risk to the patient.
  • Participation in any other study within 30 days prior to Visit 2.
  • Known medical history of allergy or sensitivity to any components of the preparations to be used in this trial that is deemed clinically significant in the opinion of the investigator.
  • Use of systemic medications known to affect IOP (e.g., oral beta-adrenergic blockers,alpha-agonists and blockers, angiotensin converting enzyme inhibitors and calcium channel blockers), which have not been on a stable course for 7 days prior to Visit 2 or an anticipated change in the dosage during the course of the study.
  • Anticipated use of systemic , by any route except inhaled, for greater than two weeks during the trial.
  • A history of, or at risk for uveitis or cystoid macular edema (CME).
  • History of ocular herpes simplex.
  • Unwillingness to accept the risk of iris, skin, or eyelash changes associated with prostaglandin therapy.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Other
    Travoprost-to-tafluprost

    Travoprost first, with tafluprost second. Each product dosed for six weeks.

    Drug: Travoprost 0.004% ophthalmic solution (TRAVATAN) · Drug: Tafluprost 0.0015% ophthalmic solution

  • Other
    Tafluprost-to-travoprost

    Tafluprost first, with travoprost second. Each product dosed for six weeks.

    Drug: Travoprost 0.004% ophthalmic solution (TRAVATAN) · Drug: Tafluprost 0.0015% ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Intraocular Pressure (IOP) at 8:00 PM

    Intraocular pressure was measured by Goldmann applanation tonometry.

    Time frame: 6 weeks

Secondary outcomes

  1. Mean Intraocular Pressure (IOP) at 8:00 AM

    Intraocular pressure was measured by Goldmann applanation tonometry.

    Time frame: 6 weeks

  2. Mean Intraocular Pressure (IOP) at 10:00 AM

    Intraocular pressure was measured by Goldmann applanation tonometry.

    Time frame: 6 weeks

  3. Mean Intraocular Pressure (IOP) at 12:00 PM

    Intraocular pressure was measured by Goldmann applanation tonometry.

    Time frame: 6 weeks

  4. Mean Intraocular Pressure (IOP) at 2:00 PM

    Intraocular pressure was measured by Goldmann applanation tonometry.

    Time frame: 6 weeks

  5. Mean Intraocular Pressure (IOP) at 4:00 PM

    Intraocular pressure was measured by Goldmann applanation tonometry.

    Time frame: 6 weeks

  6. Mean Intraocular Pressure (IOP) at 6:00 PM

    Intraocular pressure was measured by Goldmann applanation tonometry.

    Time frame: 6 weeks

07

Results

Posted Jun 20, 2012

Participant flow

Patients were recruited from four private practices located in Germany.

Period 1, First 6 Weeks
Participant flow — Period 1, First 6 Weeks
MilestoneTravoprost-to-tafluprostTafluprost-to-travoprost
Started2823
Completed2523
Not completed30
Withdrew: Withdrawal by subject20
Withdrew: Protocol violation10
Period 2, Second 6 Weeks
Participant flow — Period 2, Second 6 Weeks
MilestoneTravoprost-to-tafluprostTafluprost-to-travoprost
Started2523
Completed2523
Not completed00

Outcome measures

PrimaryMean Intraocular Pressure (IOP) at 8:00 PM

Intraocular pressure was measured by Goldmann applanation tonometry.

Time frame:
6 weeks
Reported as:
Mean · mm Hg
Mean Intraocular Pressure (IOP) at 8:00 PM
mm HgTravoprostTafluprost
Mean Intraocular Pressure (IOP) at 8:00 PM17.1 ± 3.1717.7 ± 3.23
SecondaryMean Intraocular Pressure (IOP) at 8:00 AM

Intraocular pressure was measured by Goldmann applanation tonometry.

Time frame:
6 weeks
Reported as:
Mean · mm Hg
Mean Intraocular Pressure (IOP) at 8:00 AM
mm HgTravoprostTafluprost
Mean Intraocular Pressure (IOP) at 8:00 AM17.0 ± 2.3617.5 ± 2.20
SecondaryMean Intraocular Pressure (IOP) at 10:00 AM

Intraocular pressure was measured by Goldmann applanation tonometry.

Time frame:
6 weeks
Reported as:
Mean · mm Hg
Mean Intraocular Pressure (IOP) at 10:00 AM
mm HgTravoprostTafluprost
Mean Intraocular Pressure (IOP) at 10:00 AM16.7 ± 2.3917.3 ± 2.50
SecondaryMean Intraocular Pressure (IOP) at 12:00 PM

Intraocular pressure was measured by Goldmann applanation tonometry.

Time frame:
6 weeks
Reported as:
Mean · mm Hg
Mean Intraocular Pressure (IOP) at 12:00 PM
mm HgTravoprostTafluprost
Mean Intraocular Pressure (IOP) at 12:00 PM16.7 ± 2.4717.2 ± 2.46
SecondaryMean Intraocular Pressure (IOP) at 2:00 PM

Intraocular pressure was measured by Goldmann applanation tonometry.

Time frame:
6 weeks
Reported as:
Mean · mm Hg
Mean Intraocular Pressure (IOP) at 2:00 PM
mm HgTravoprostTafluprost
Mean Intraocular Pressure (IOP) at 2:00 PM16.9 ± 2.6917.3 ± 2.77
SecondaryMean Intraocular Pressure (IOP) at 4:00 PM

Intraocular pressure was measured by Goldmann applanation tonometry.

Time frame:
6 weeks
Reported as:
Mean · mm Hg
Mean Intraocular Pressure (IOP) at 4:00 PM
mm HgTravoprostTafluprost
Mean Intraocular Pressure (IOP) at 4:00 PM17.1 ± 2.8517.6 ± 2.80
SecondaryMean Intraocular Pressure (IOP) at 6:00 PM

Intraocular pressure was measured by Goldmann applanation tonometry.

Time frame:
6 weeks
Reported as:
Mean · mm Hg
Mean Intraocular Pressure (IOP) at 6:00 PM
mm HgTravoprostTafluprost
Mean Intraocular Pressure (IOP) at 6:00 PM16.9 ± 3.1217.6 ± 3.13

Adverse events

Collected over Adverse events were collected for the duration of the study: 10-September-2009 to 2-March-2010.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travoprost—0/51 (0%)0/51 (0%)
Tafluprost—0/48 (0%)0/48 (0%)

Baseline characteristics

Age Continuous
Age Continuous(years)Travoprost-to-tafluprostTafluprost-to-travoprostTotal
Mean69.1 ± 7.868.5 ± 10.568.8 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Travoprost-to-tafluprostTafluprost-to-travoprostTotal
Female161531
Male12820
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2009
First posted
Aug 27, 2009
Start
Sep 2009
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Jun 20, 2012
Last update
Jun 20, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00966940
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Aug 27, 2009
Start date
Sep 2009
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Jun 20, 2012
Last update
Jun 20, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Travoprost · Tafluprost

Start the discussion